Gilead Sciences, (GILD) Financials
Gilead Sciences, (GILD) Historical Financial Statements and Key Metrics for 1996 - 2025
Full Gilead Sciences, financials for 1996 - 2025 are available in the
US Historical Financials dataset
All financial data is sourced direct from SEC 10-Q and 10-K filings, restatements are included.
Gilead Sciences, Income Statements
(in $ 000,000's)
| Quarter End | Revenue | Gross Profit | Operating Income | Net Income | EBITDA | EPS |
| 2025-Mar-31 | 6,667 | 5,127 (76.9 %) | 2,237 (33.6 %) | 1,315 (19.7 %) | 2,605 | 1.04 |
| 2024-Dec-31 | 7,569 | 5,988 (79.1 %) | 2,451 (32.4 %) | 1,783 (23.6 %) | 3,109 | 1.42 |
| 2024-Sep-30 | 7,545 | 5,971 (79.1 %) | 888 (11.8 %) | 1,253 (16.6 %) | 1,884 | 1.00 |
| 2024-Jun-30 | 6,949 | 5,405 (77.8 %) | 2,688 (38.7 %) | 1,614 (23.2 %) | 3,382 | 1.29 |
| 2024-Mar-31 | 6,686 | 5,134 (76.8 %) | 2,302 (34.4 %) | -4,170 (-62.4 %) | 2,992 | -3.34 |
| 2023-Dec-31 | 7,115 | 5,555 (78.1 %) | 2,506 (35.2 %) | 1,429 (20.1 %) | 3,139 | 1.14 |
| 2023-Sep-30 | 7,050 | 5,485 (77.8 %) | 2,623 (37.2 %) | 2,180 (30.9 %) | 2,641 | 1.73 |
Full historical income statements for 1996 - 2025 is included in the
US Historical Financials dataset.
Gilead Sciences, Balance Sheets
(in $ 000,000's)
| Quarter End | Total Assets | Total Liabilities | Total Debt | Total Equity | Cash & Equivalents |
| 2025-Mar-31 | 56,434 | 37,356 | 24,952 | 19,162 | 7,926 |
| 2024-Dec-31 | 58,995 | 39,749 | 26,711 | 19,330 | 9,991 |
| 2024-Sep-30 | 54,525 | 36,135 | 23,249 | 18,474 | 5,037 |
| 2024-Jun-30 | 53,579 | 35,384 | 23,350 | 18,281 | 4,198 |
| 2024-Mar-31 | 56,292 | 38,837 | 25,194 | 17,539 | 6,059 |
| 2023-Dec-31 | 62,125 | 39,376 | 24,987 | 22,749 | 8,428 |
| 2023-Sep-30 | 62,373 | 40,131 | 25,906 | 22,242 | 8,021 |
Full historical balance sheet data for 1996 - 2025 is included in the
US Historical Financials dataset.
Gilead Sciences, Cash Flow Statements
(in $ 000,000's)
| Quarter End | Operating Cash Flow | Investing | Financing | Free Cash Flow |
| 2025-Mar-31 | 1,757 | -415 | -3,426 | 1,653 |
| 2024-Dec-31 | 2,975 | -225 | 2,260 | 2,975 |
| 2024-Sep-30 | 4,309 | -710 | -1,379 | 4,168 |
| 2024-Jun-30 | 1,325 | -307 | -2,953 | 1,195 |
| 2024-Mar-31 | 2,219 | -2,207 | -1,361 | 2,114 |
| 2023-Dec-31 | 2,169 | -727 | -1,099 | 1,954 |
| 2023-Sep-30 | 1,756 | -229 | -1,518 | 1,756 |
Full historical cash flow data for 1996 - 2025 is included in the
US Historical Financials dataset.
Gilead Sciences, Key Valuation and Operating Metrics
| Quarter End | Market Capitalization ($ 000,000's) |
Enterprise Value ($ 000,000's) |
Price/Earnings ($ 000,000's) |
Price/Sales ($ 000,000's) |
Price/Book ($ 000,000's) |
| 2025-Mar-31 | 139,614 | 156,640 | 20.94 | 26.54 | 7.29 |
| 2024-Dec-31 | 115,278 | 131,998 | 15.23 | 16.16 | 5.96 |
| 2024-Sep-30 | 104,548 | 122,760 | 13.86 | 20.86 | 5.66 |
| 2024-Jun-30 | 85,594 | 106,172 | 12.32 | 13.26 | 4.68 |
| 2024-Mar-31 | 90,881 | 111,357 | 13.59 | -5.45 | 5.18 |
| 2023-Dec-31 | 101,100 | 120,002 | 14.21 | 17.69 | 4.44 |
| 2023-Sep-30 | 93,525 | 113,726 | 13.27 | 10.73 | 4.20 |
Full historical valuation and operating metrics for 1996 - 2025 are included in the
US Historical Financials dataset.